On the back of positive data presented at the recently concluded ASH meeting, Kite filed for approval of KTE-X19 in mantle cell lymphoma. The company currently markets another CAR-T, Yescarta, for a different form of lymphoma.
More than years after its initial approval, Kymriah has shown comparable efficacy and an apparently better safety profile than it demonstrated in the studies that led to its leukemia and lymphoma approvals. Another therapy, made by BMS, is a potential competitor.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company is developing the drug, MGTA-145 as a one-day stem cell-mobilization product, compared with current standard G-CSF, which must be administered over several days and is associated with severe side effects.
In data from several clinical trials released Friday and during the weekend, cell and other therapies for multiple myeloma targeting the antigen BCMA showed strong response rates.
ArQule's lead product candidate is a BTK inhibitor, ARQ-531, designed for heavily pretreated patients with leukemias and lymphomas, particularly those whose disease has become resistant to marketed BTK therapies. Phase I data on the drug were also presented Monday.
Data showed LOXO-305 was broadly effective in patients resistant to BTK inhibitors regardless of whether they harbored a putative mechanism of resistance to the widely used blood cancer drugs.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.